Study of Aprepitant / Palonosetron / Dexamethasone for nausea and vomiting induced chemotherapy for breast cancer. - Study of Aprepitant / Palonosetron / Dexamethasone for nausea and vomiting

Saitama Breast Cancer Clinical Study Group(SBCCSG)0 个研究点目标入组 55 人开始时间: 2010年8月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The exclusion criteria were as follows; patients were not eligible for this study if 1) Advanced or Recurrent breast Cancer. 2) child-pugh score > 9 3) they had undergone treatment with high emetic risk and moderate emetic risk chemotherapy by Japan society of clinical oncology prior to this study 4) they had undergone treatment with clarithromycin, ketoconazole, itraconazole within 7 days 5) they had undergone treatment with barbiturate, rifampicin, phenytoin, carbamazepine within 4 weeks. 6) they took warfarin. 7) they took oral contraceptive. 8) they had deep venous thrombosis 9) they had ascites or pleural effusion needs paracentesis treatment. 10) they had serious complication. (intestinal paralysis, lung fibrosis, diabetes mellitus, heart failure, myocardial infarction, angina pectoris, renal failure, psychiatric disorder, cerebrovascular accident, active gastric ulcer, active duodenal ulcer. 11) they had an associated symptom (ex infectious disease) patient who can not administer dexamethasone for 4 days. 12) they had a brain metastasis or suspected case. 13) they were operated within 28 day before entry 14) they operated radiation therapy 15) they except referred to above, physician in charge of this trial gave a diagnosis the patient who can not joint this trail for the safety.

发起方

Saitama Breast Cancer Clinical Study Group(SBCCSG)